Literature DB >> 10709098

Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma.

A Borg1, J Isola, J Chen, C Rubio, U Johansson, B Werelius, A Lindblom.   

Abstract

Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant disease, predisposing to the development of colorectal cancer and other tumor types such as endometrial, small bowel, stomach, ovary and urinary tract carcinoma, while most investigators find no association between HNPCC and cancer of the breast. We have identified hMLH1 mutations in 2 Amsterdam-criteria HNPCC families where both male and female gene carriers were affected with breast cancer. To investigate whether these breast cancers were caused by other genetic factors, we analyzed the 2 breast cancer susceptibility genes BRCA1 and BRCA2. In one family we did not find any mutation in the breast cancer genes, while in the other, a BRCA1 mutation segregated in the breast cancer cases. Hereditary breast cancer, and in particular BRCA1 tumors, display discrete histo-pathological and immunohistological characteristics. The tumor from a woman with both hMLH1 mutations and a BRCA1 mutation exhibited typical BRCA1 histology, e.g., grade 3 invasive ductal carcinoma with dense lymphocytic infiltration, and immunohistology, estrogen receptor (ER) negative, progesterone receptor (PgR) negative, strongly p53 positive, c-erbB-2 negative and highly Ki67 positive (>50% stained cells). The histology of the breast tumor from the man with both one hMLH1 mutation and a BRCA1 mutation was a grade 2 invasive ductal carcinoma without any special BRCA1 features. Immunohistology was also different. This might merely reflect a true difference in male breast tumor progression vs. female. We cannot exclude that the combined effect of BRCA1 and hMLH1 dysfunction has a bearing on tumor progression. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10709098     DOI: 10.1002/(sici)1097-0215(20000315)85:6<796::aid-ijc10>3.0.co;2-l

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Delineating a new feature of constitutional mismatch repair deficiency (CMMRD) syndrome: breast cancer.

Authors:  Lisa Bush; Melyssa Aronson; Uri Tabori; Brittany B Campbell; Raymond B Bedgood; Kory Jasperson
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

2.  Analysis for phenotype of HNPCC in China.

Authors:  Yong-Mao Song; Shu Zheng
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

3.  Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling.

Authors:  A Liede; K Metcalfe; D Hanna; E Hoodfar; C Snyder; C Durham; H T Lynch; S A Narod
Journal:  Am J Hum Genet       Date:  2000-11-03       Impact factor: 11.025

4.  Assay validation for identification of hereditary nonpolyposis colon cancer-causing mutations in mismatch repair genes MLH1, MSH2, and MSH6.

Authors:  Madhuri Hegde; Maria Blazo; Belinda Chong; Tom Prior; Carolyn Richards
Journal:  J Mol Diagn       Date:  2005-10       Impact factor: 5.568

5.  Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy.

Authors:  Tadeusz Majewski; Sangkyou Lee; Joon Jeong; Dong-Sup Yoon; Andrzej Kram; Mi-Sook Kim; Tomasz Tuziak; Jolanta Bondaruk; Sooyong Lee; Weon-Seo Park; Kuang S Tang; Woonbok Chung; Lanlan Shen; Saira S Ahmed; Dennis A Johnston; H Barton Grossman; Colin P Dinney; Jain-Hua Zhou; R Alan Harris; Carrie Snyder; Slawomir Filipek; Steven A Narod; Patrice Watson; Henry T Lynch; Adi Gazdar; Menashe Bar-Eli; Xifeng F Wu; David J McConkey; Keith Baggerly; Jean-Pierre Issa; William F Benedict; Steven E Scherer; Bogdan Czerniak
Journal:  Lab Invest       Date:  2008-05-05       Impact factor: 5.662

6.  Familial breast and bowel cancer: does it exist?

Authors:  Rodney J Scott; Katie A Ashton
Journal:  Hered Cancer Clin Pract       Date:  2004-02-15       Impact factor: 2.857

Review 7.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

8.  Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors.

Authors:  M Pedroni; C Di Gregorio; L Cortesi; L Reggiani Bonetti; G Magnani; M L Simone; V Medici; C Priore Oliva; M Marino; M Ponz de Leon
Journal:  Tech Coloproctol       Date:  2013-05-22       Impact factor: 3.781

9.  BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.

Authors:  Christian Monnerat; Agnès Chompret; Caroline Kannengiesser; Marie-Françoise Avril; Nicolas Janin; Alain Spatz; Jean-Marc Guinebretière; Catalin Marian; Michel Barrois; Françoise Boitier; Gilbert M Lenoir; Brigitte Bressac-de Paillerets
Journal:  Fam Cancer       Date:  2007-07-12       Impact factor: 2.375

10.  Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.

Authors:  Minjie Wei; Jinhua Xu; James Dignam; Rita Nanda; Lise Sveen; James Fackenthal; Tatyana A Grushko; Olufunmilayo I Olopade
Journal:  Breast Cancer Res Treat       Date:  2007-10-12       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.